- Trutect™ (Canine Parvovirus Monoclonal Antibody) is now fully USDA approved after conditional licensure in 2023.
- Clinical and real-world data show a 93% survival rate among treated puppies.
- The USDA expanded approval in 2025 to include passive immunity, enabling preventive use.
- Elanco has donated more than $3 million of product to shelters and clinics in high-risk areas.
- The company is offering a $200 rebate for pet owners whose puppies are infected or exposed.
First Fully Approved Parvovirus Treatment Now Under Elanco’s Tru Portfolio
Elanco Animal Health announced that its Canine Parvovirus Monoclonal Antibody (CPMA) has received full approval from the U.S. Department of Agriculture (USDA) and will now be marketed as Trutect™, the first and only approved treatment for canine parvovirus (parvo).
Parvovirus remains one of the most lethal infectious diseases in dogs, affecting more than 330,000 puppies annually and carrying a mortality rate of up to 91% without supportive care. Prior to CPMA’s introduction, treatment was limited to supportive therapy.
“Receiving full USDA approval of our lifesaving parvo treatment reinforces our promise to go beyond for veterinarians, pet owners, and the puppies who need it most,” said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco. “Under the Trutect brand, our mission remains the same—to save puppies from parvovirus.”
Strong Real-World Impact and Clinical Results
Since its conditional approval in May 2023, Trutect has helped save thousands of puppies nationwide. Real-world data collected over the first year showed:
- 93% survival among puppies treated with CPMA
- 1.87 fewer hospitalization days on average per patient
- 92% of veterinarians reported reduced clinic stress when using the therapy
- 90% clinic satisfaction with integration into treatment protocols
- 83% of veterinarians would recommend the therapy to peers
“The data demonstrate improved survival and enhanced clinic efficiency,” said Dr. Jill Pattee, veterinarian at Elanco Animal Health. “Trutect has already begun redefining how we manage parvovirus cases.”
Expanded Indication for Preventive Use
In June 2025, the USDA approved Trutect for passive immunity, allowing veterinarians to administer the product prophylactically to puppies exposed to parvovirus. In a recent study, Trutect provided 100% protection to healthy puppies aged eight weeks or older against parvo infection.
“The results highlight Trutect’s ability to stop parvo before it starts,” said Dr. Pattee. “This offers veterinarians a critical new tool to protect vulnerable puppies.”
Emergency veterinarian Dr. Tannetje Crocker of the Veterinary Emergency Group in Dallas added, “I’ve seen firsthand the devastating impact of parvo. Trutect has allowed me to save countless puppies and prevent infection in exposed dogs. Every clinic should have it on hand.”
Expanding Access and Awareness
Elanco has distributed more than $3 million in donated product to 2,300 clinics and shelters in high-parvo regions. The company has also continued to expand its Elwood, Kansas manufacturing facility to scale monoclonal antibody production.
In addition to product donations, Elanco offers a $200 rebate for pet owners treating puppies infected or exposed to parvo. The company’s ongoing “Defend Puppies. Defeat Parvo.” initiative and National Parvo Awareness Day campaign further raise public awareness about prevention and treatment.
For more information, visit DefeatParvo.com.
Information sourced from Elanco Animal Health’s press release.
